dosage is further increased to 2000 mg divided into three fractions -700, 600, and 700 mg.
On January 9 total serum VA concentration was 1.04 µg/ml, albumin levels were 2,5 g/dl, and serum free VA concentration was non detectable. At this time the pharmacy department recommended the discontinuation of ertapenem and that VA be administered intravenously using a load dose of 800 mg and a maintenance dose of 400 mg/6 h. After having initiated this dosage scheme total serum VA levels of 14.83 µg/ml (free 1.76 µg/ml) were found on January 11, of 15.43 µg/ml (free 2.20 µg/ml) on January 13, of 23.65 µg/ml (free 3,86 µg/ml) on January 16, and of 28.92 µg/ml (free 7.12 µg/ml) on January 20. Once free VA levels had returned within the therapeutic range (5-10 µg/ml) the enteral route is reinitiated with a dosage of 1400 mg/day divided into three parts -500, 400, 500 mg-not coincidental with nutrition. With this dosage the patient kept her free VA plasma concentrations within the therapeutic range.
Discussion
The EMEA's assessment report on ertapenem 1 states that "no studies have been performed on the interaction between VA and ertapenem, but […] carbapenems reduce serum VA levels". Indeed, recent scientific literature reports on several cases of pharmacokinetic interaction between VA and panipenem 2 , meropenem 2-5 , or imipenem 3, 5 , but no reference can be found in MedLine or EMBASE describing the VA-ertapenem interaction suggested by our data.
Panipenem, meropenem, and imipenem 2-5 induce a marked decrease in plasma VA concentrations between days one and nine after antibiotic onset, which starts to recover at 24 hours following antibiotic discontinuation, and returns to normal after 3-17 days. In our case subtherapeutic VA concentrations are identified on the fourth day after ertapenem onset -they eventually fall by 97% and do not recover on increasing VA dose, but do finally ascend upon ertapenem discontinuation, and reach therapeutic free VA concentrations after eleven days.
The mechanism underlying the interaction between carbapenems and VA has not been elucidated. It is suggested 6 that panipenem increases intrinsic hepatic clearance for VA by activating liver glycogenolysis, increasing UDP-glucuronic acid levels, and enhancing VA glucuronization. Some authors 7 posit that imipenem inhibits VA intestinal absorption; others 8 claim a dual mechanism with increased renal clearance and reduced liver hydrolysis for VA-glucuronide by effect of carbapenems. Another potential mechanism is also suggested 5 , according to which imipenem and panipenem would increase in vivo VA distribution among red blood cells, thus diminishing VA plasma concentration.
None of the studies attempting to explain the effects of carbapenem antimicrobials on VA and VA metabolite pharmacokinetics is conclusive, but fact as made up with recorded cases is. There is a highly significant pharmacokinetic interaction between carbapenems and valproic acid that is well documented in the literature regarding imipenem, meropenem, and panipenem, and which can be now extended to ertapenem in view of our clinical case report.
Despite the fact that ertapenem is less convulsant when compared to other carbapenems 1 , the administration of any of these compounds to patients receiving VA may entail a significant risk for seizures. In such case, when both antibiotic and anticonvulsant coverage is required, a different antibiotic should be selected in accordance with the isolated organism's sensitivity, or a different anticonvulsant should be substituted for VA. 
